Dynavax Technologies (DVAX) Reaches $18.00 After 3.00% Down Move; 13 Analysts Are Bullish Allscripts Healthcare Solutions, Inc. (MDRX) Last Week

April 24, 2018 - By Louis Casey

Allscripts Healthcare Solutions, Inc. (NASDAQ:MDRX) Logo

Among 26 analysts covering Allscripts-Misys Healthcare (NASDAQ:MDRX), 13 have Buy rating, 1 Sell and 12 Hold. Therefore 50% are positive. Allscripts-Misys Healthcare had 69 analyst reports since August 5, 2015 according to SRatingsIntel. Piper Jaffray maintained it with “Hold” rating and $15.0 target in Friday, February 16 report. The stock of Allscripts Healthcare Solutions, Inc. (NASDAQ:MDRX) earned “Buy” rating by Cantor Fitzgerald on Thursday, February 15. Robert W. Baird maintained it with “Buy” rating and $16.0 target in Friday, September 15 report. Leerink Swann downgraded Allscripts Healthcare Solutions, Inc. (NASDAQ:MDRX) on Monday, June 19 to “Market Perform” rating. The firm has “Overweight” rating by Cantor Fitzgerald given on Tuesday, August 15. Cowen & Co maintained the shares of MDRX in report on Wednesday, April 18 with “Buy” rating. On Thursday, November 10 the stock rating was downgraded by Deutsche Bank to “Hold”. Maxim Group maintained the stock with “Buy” rating in Tuesday, January 10 report. Cantor Fitzgerald maintained Allscripts Healthcare Solutions, Inc. (NASDAQ:MDRX) rating on Tuesday, March 27. Cantor Fitzgerald has “Buy” rating and $1800 target. Robert W. Baird maintained the shares of MDRX in report on Friday, November 3 with “Outperform” rating. See Allscripts Healthcare Solutions, Inc. (NASDAQ:MDRX) latest ratings:

18/04/2018 Broker: Cowen & Co Rating: Buy New Target: $16.0000 Maintain
05/04/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $18.0000 Maintain
27/03/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $18.0000 Maintain
06/03/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $18.0 Maintain
27/02/2018 Broker: Bank of America Rating: Buy New Target: $17.0
16/02/2018 Broker: Wells Fargo Rating: Buy New Target: $19.0
16/02/2018 Broker: Piper Jaffray Rating: Hold New Target: $15.0 Maintain
16/02/2018 Broker: Canaccord Genuity Rating: Buy New Target: $17.0 Maintain
15/02/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $18.0 Maintain
19/01/2018 Broker: Evercore Rating: Outperform New Target: $17.5 Initiates Coverage On

The stock of Dynavax Technologies Corporation (NASDAQ:DVAX) is a huge mover today! The stock decreased 2.44% or $0.45 during the last trading session, reaching $18. About 371,317 shares traded. Dynavax Technologies Corporation (NASDAQ:DVAX) has risen 231.67% since April 24, 2017 and is uptrending. It has outperformed by 220.12% the S&P500.The move comes after 8 months negative chart setup for the $1.12 billion company. It was reported on Apr, 24 by Barchart.com. We have $17.46 PT which if reached, will make NASDAQ:DVAX worth $33.63M less.

Allscripts Healthcare Solutions, Inc. provides information technology and services to healthcare organizations in the United States, Canada, and internationally. The company has market cap of $2.19 billion. It offers electronic health records, connectivity, private cloud hosting, outsourcing, analytics, patient engagement, clinical decision support, and population health management solutions. It currently has negative earnings. The companyÂ’s Clinical and Financial Solutions segment provides integrated clinical software applications and financial and information solutions, which primarily include EHR-related, and financial and practice management software solutions, as well as related installation, support and maintenance, outsourcing, private cloud hosting, revenue cycle management, training, and electronic claims administration services.

Investors sentiment decreased to 0.98 in 2017 Q4. Its down 0.18, from 1.16 in 2017Q3. It fall, as 27 investors sold Allscripts Healthcare Solutions, Inc. shares while 77 reduced holdings. 36 funds opened positions while 66 raised stakes. 187.17 million shares or 4.38% less from 195.75 million shares in 2017Q3 were reported. Janney Montgomery Scott Limited Co invested 0.01% in Allscripts Healthcare Solutions, Inc. (NASDAQ:MDRX). Sterling Cap Limited Liability accumulated 96,937 shares. Advantus Capital Mgmt Incorporated stated it has 22,254 shares. Alliancebernstein Limited Partnership invested in 0% or 441,534 shares. 2.72 million are owned by Morgan Stanley. Atwood And Palmer Incorporated owns 1,925 shares or 0% of their US portfolio. Staley Cap Advisers owns 0.06% invested in Allscripts Healthcare Solutions, Inc. (NASDAQ:MDRX) for 54,903 shares. The Illinois-based Grp Inc One Trading Ltd Partnership has invested 0% in Allscripts Healthcare Solutions, Inc. (NASDAQ:MDRX). Jacobs Levy Equity Incorporated invested in 1.35M shares or 0.34% of the stock. Ls Advisors Limited Liability Co has invested 0.01% in Allscripts Healthcare Solutions, Inc. (NASDAQ:MDRX). 431,138 were accumulated by Manufacturers Life The. North Star Invest Mgmt Corp accumulated 6 shares. Moreover, Fisher Asset Mngmt Ltd Co has 0.05% invested in Allscripts Healthcare Solutions, Inc. (NASDAQ:MDRX) for 2.39 million shares. Mesirow Financial Management stated it has 1.31% in Allscripts Healthcare Solutions, Inc. (NASDAQ:MDRX). Texas Permanent School Fund has invested 0.02% of its portfolio in Allscripts Healthcare Solutions, Inc. (NASDAQ:MDRX).

The stock increased 0.74% or $0.09 during the last trading session, reaching $12.32. About 772,411 shares traded. Allscripts Healthcare Solutions, Inc. (NASDAQ:MDRX) has declined 6.63% since April 24, 2017 and is downtrending. It has underperformed by 18.18% the S&P500.

Since December 14, 2017, it had 0 insider purchases, and 5 insider sales for $772,395 activity. Farley Brian sold $68,629 worth of Allscripts Healthcare Solutions, Inc. (NASDAQ:MDRX) on Wednesday, March 14. $215,292 worth of Allscripts Healthcare Solutions, Inc. (NASDAQ:MDRX) was sold by Black Paul. Shares for $213,840 were sold by Poulton Richard J..

Analysts await Dynavax Technologies Corporation (NASDAQ:DVAX) to report earnings on May, 14. They expect $-0.51 earnings per share, up 8.93% or $0.05 from last year’s $-0.56 per share. After $-0.43 actual earnings per share reported by Dynavax Technologies Corporation for the previous quarter, Wall Street now forecasts 18.60% negative EPS growth.

Among 6 analysts covering Dynavax Technologies (NASDAQ:DVAX), 4 have Buy rating, 0 Sell and 2 Hold. Therefore 67% are positive. Dynavax Technologies has $48 highest and $700 lowest target. $27.43’s average target is 52.39% above currents $18 stock price. Dynavax Technologies had 27 analyst reports since August 12, 2015 according to SRatingsIntel. RBC Capital Markets downgraded the shares of DVAX in report on Thursday, April 28 to “Sector Perform” rating. JP Morgan downgraded it to “Neutral” rating and $22 target in Wednesday, April 27 report. The stock of Dynavax Technologies Corporation (NASDAQ:DVAX) earned “Outperform” rating by RBC Capital Markets on Monday, November 30. William Blair maintained Dynavax Technologies Corporation (NASDAQ:DVAX) on Friday, July 21 with “Buy” rating. The stock of Dynavax Technologies Corporation (NASDAQ:DVAX) earned “Buy” rating by Cantor Fitzgerald on Monday, April 16. The stock of Dynavax Technologies Corporation (NASDAQ:DVAX) earned “Outperform” rating by RBC Capital Markets on Monday, July 31. The stock of Dynavax Technologies Corporation (NASDAQ:DVAX) earned “Hold” rating by J.P. Morgan on Wednesday, February 14. Cantor Fitzgerald maintained the shares of DVAX in report on Wednesday, September 27 with “Buy” rating. Zacks upgraded the shares of DVAX in report on Wednesday, August 12 to “Hold” rating. J.P. Morgan upgraded Dynavax Technologies Corporation (NASDAQ:DVAX) on Monday, July 31 to “Buy” rating.

Since December 13, 2017, it had 0 buys, and 5 insider sales for $1.07 million activity. Novack David F had sold 34,214 shares worth $565,105. 3,092 shares were sold by Johnson David Louis, worth $57,511 on Thursday, January 4. COFFMAN ROBERT also sold $141,750 worth of Dynavax Technologies Corporation (NASDAQ:DVAX) shares.

Investors sentiment decreased to 1 in 2017 Q4. Its down 1.06, from 2.06 in 2017Q3. It turned negative, as 15 investors sold Dynavax Technologies Corporation shares while 43 reduced holdings. 31 funds opened positions while 27 raised stakes. 43.53 million shares or 3.88% more from 41.91 million shares in 2017Q3 were reported. Swiss National Bank owns 99,878 shares or 0% of their US portfolio. Guggenheim Capital Limited holds 0% in Dynavax Technologies Corporation (NASDAQ:DVAX) or 104,756 shares. Citadel Advisors Lc owns 225,299 shares. Blair William Il holds 0.25% or 1.98M shares in its portfolio. 47,716 are owned by Manufacturers Life Insur Com The. Moreover, Atlantic Gp Ltd Limited Liability Company has 0% invested in Dynavax Technologies Corporation (NASDAQ:DVAX). Invesco Ltd has 496,592 shares. Assetmark has 0% invested in Dynavax Technologies Corporation (NASDAQ:DVAX) for 69 shares. Creative Planning reported 230,848 shares stake. 3.81 million are held by Point72 Asset Mngmt L P. Vantage Invest Ltd Llc reported 0% stake. Ubs Asset Management Americas invested in 0% or 24,860 shares. Renaissance Techs Limited Liability has invested 0% in Dynavax Technologies Corporation (NASDAQ:DVAX). Lord Abbett Commerce Ltd Liability Company holds 0.03% or 517,150 shares. Bnp Paribas Arbitrage holds 12,720 shares or 0% of its portfolio.

Allscripts Healthcare Solutions, Inc. (NASDAQ:MDRX) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts